hLife, Год журнала: 2023, Номер 2(3), С. 141 - 146
Опубликована: Дек. 22, 2023
Язык: Английский
Cell Reports, Год журнала: 2025, Номер 44(1), С. 115168 - 115168
Опубликована: Янв. 1, 2025
Highlights•Cryo-EM structure of EBV gp350-CR2 complex at a resolution 3.29 Å•Depiction polar and glycan-free contacting interface•Key residue divergence in CR2 affects host tropism•Designed CR2-Fc neutralizes B cell infection by targeting 72A1 epitopeSummaryEpstein-Barr virus (EBV) is an oncogenic associated with multiple lymphoid malignancies autoimmune diseases. During cells, uses its major glycoprotein gp350 to recognize the receptor CR2, initiating viral attachment, process that has lacked direct structural evidence for decades. In this study, we resolved complex, elucidated their key interactions, determined site-specific N-glycosylation map gp350. Our findings reveal primarily binds through electrostatically complementary interface diversity residues across different species influences selectivity mediated With confirmed binding, constructed antibody analog targets vulnerable site gp350, demonstrating potent neutralization effect against cells. work provides essential insights into mechanism tropism, suggesting potential antiviral agent.Graphical abstract
Язык: Английский
Процитировано
2
Animal Models and Experimental Medicine, Год журнала: 2025, Номер unknown
Опубликована: Фев. 7, 2025
Human herpesvirus, a specific group within the herpesvirus family, is responsible for variety of human diseases. These viruses can infect humans and other vertebrates, primarily targeting skin, mucous membranes, neural tissues, thereby significantly impacting health both animals. Animal models are crucial studying virus pathogenesis, vaccine development, drug testing. Despite several candidates being in preclinical clinical stages, no vaccines current available to prevent lifelong infections caused by these herpesviruses, except varicella-zoster (VZV) vaccine. However, strict host tropism herpesviruses limitations mean that single animal model fully replicate all key features herpesvirus-associated This makes it challenging evaluate antivirals against comprehensively. Herein, we summarize used study including α-herpesviruses (herpes simplex type 1(HSV-1), HSV-2, VZV), β-herpesviruses (human cytomegalovirus (HCMV), γ-herpesviruses (Epstein-Barr (EBV)) Kaposi's sarcoma (KSHV)). By providing concise information detailed analysis potential, applications various models, such as non-human primates, mice, rabbits, guinea pigs, tree shrews, this summary aims help researchers efficiently select most appropriate model, offering practical guidance herpesvirus.
Язык: Английский
Процитировано
2
Biochemical Pharmacology, Год журнала: 2024, Номер 225, С. 116270 - 116270
Опубликована: Май 10, 2024
Язык: Английский
Процитировано
8
Frontiers in Cellular and Infection Microbiology, Год журнала: 2024, Номер 14
Опубликована: Июнь 26, 2024
The Coronavirus Disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has incurred devastating human and economic losses. Vaccination remains most effective approach for controlling COVID-19 pandemic. Nonetheless, sustained evolution of SARS-CoV-2 variants provoked concerns among scientific community regarding development next-generation vaccines. Among these, given their safety, immunogenicity, flexibility to display varied native epitopes, virus-like particle (VLP)-based vaccines represent one promising In this review, we summarize advantages characteristics VLP platforms, strategies antigen display, current clinical trial progress based on platforms. Importantly, experience lessons learned from provide insights into prevent future pandemics other epidemics.
Язык: Английский
Процитировано
7
npj Vaccines, Год журнала: 2024, Номер 9(1)
Опубликована: Авг. 31, 2024
Nipah virus (NiV) is a zoonotic emergent paramyxovirus that can cause severe encephalitis and respiratory infections in humans, with high fatality rate ranging from 40% to 75%. Currently, there are no approved human vaccines or antiviral drugs against NiV. Here, we designed ferritin-based self-assembling nanoparticle displaying the NiV G head domain on surface (NiV G-ferritin) assessed immune responses elicited by soluble sG) G-ferritin. Immunization G-ferritin sG conferred complete protection lethal challenge without detection of viral RNA Syrian golden hamsters. Compared sG, induced significantly faster, broader, higher serum neutralizing three pathogenic henipaviruses (NiV-Malaysia, NiV-Bangladesh, Hendra virus). Moreover, durable immunity mice as antisera potently inhibited infection even after six months third immunization. Additionally, isolated panel 27 G-binding monoclonal antibodies (mAbs) immunized found these mAbs targeted four distinct antigenic sites two have not been defined previously. Notably, 25 potent activity 50% inhibitory concentrations less than 10 ng/mL pseudovirus. Collectively, findings provide new insights into immunogenicity protein reveal safe highly effective vaccine candidate infection.
Язык: Английский
Процитировано
6
Science China Life Sciences, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 4, 2024
Язык: Английский
Процитировано
6
Cell Reports Medicine, Год журнала: 2024, Номер 5(5), С. 101573 - 101573
Опубликована: Май 1, 2024
Epstein-Barr virus (EBV) is linked to various malignancies and autoimmune diseases, posing a significant global health challenge due the lack of specific treatments or vaccines. Despite its crucial role in EBV infection B cells, mechanisms glycoprotein gp42 remain elusive. In this study, we construct an antibody phage library from 100 EBV-positive individuals, leading identification two human monoclonal antibodies, 2B7 2C1. These antibodies effectively neutralize vitro vivo while preserving gp42's interaction with leukocyte antigen class II (HLA-II) receptor. Structural analysis unveils their distinct binding epitopes on gp42, different HLA-II site. Furthermore, both 2C1 demonstrate potent neutralization HLA-II-positive epithelial expanding our understanding role. Overall, study introduces anti-gp42 potential implications for developing vaccines targeting epitopes, addressing critical gap research.
Язык: Английский
Процитировано
5
npj Vaccines, Год журнала: 2024, Номер 9(1)
Опубликована: Июнь 26, 2024
Abstract Epstein-Barr virus (EBV) is associated with several malignancies, neurodegenerative disorders and the causative agent of infectious mononucleosis. A vaccine that prevents EBV-driven morbidity mortality remains an unmet need. EBV orally transmitted, infecting both B cells epithelial cells. Several virally encoded proteins are involved in entry. The gH/gL glycoprotein complex essential for infectivity irrespective cell type, while gp42 infection gp350 promotes viral attachment by binding to CD21 or CD35 most abundant on virion. gH/gL, gp350, known targets neutralizing antibodies therefore relevant immunogens development. Here, we developed optimized delivery alphavirus-derived replicon RNA (repRNA) candidates encoding gH/gL/gp42 delivered a cationic nanocarrier termed LION™. lead candidate, full-length elicited high titers persisted at least 8 months vaccine-specific CD8 + T response. Transfer vaccine-elicited IgG protected humanized mice from tumor formation death following high-dose challenge. These data demonstrate LION/repRNA-gH/gL ideal candidate preventing and/or related malignancies humans.
Язык: Английский
Процитировано
4
Archives of Virology, Год журнала: 2024, Номер 169(8)
Опубликована: Июль 17, 2024
Язык: Английский
Процитировано
4
Vaccines, Год журнала: 2024, Номер 12(9), С. 1002 - 1002
Опубликована: Сен. 1, 2024
Traditional vaccines can be classified into inactivated vaccines, live attenuated and subunit given orally or via intramuscular (IM) injection subcutaneous (SC) for the prevention of infectious diseases. Recently, recombinant protein DNA mRNA multiple/alternative administering route (e.g., microneedle inhalation) have been developed to make more secure, effective, tolerable, universal public. In addition preventing diseases, novel currently are being prevent cure noninfectious including cancer. These vaccine platforms using various biotechnologies such as viral vectors, nanoparticles, mRNA, recombination DNA, subunit, adjuvants, other delivery systems. this review, we will explore development applying biotechnologies, based on administration routes, viruses applied cancer prevention, therapeutic vaccines.
Язык: Английский
Процитировано
4